Clinical trial

A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy

NCT01497652

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Rasagiline/Placebo Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Rasagiline Normalized identity: rasagilineView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-01-01

PhasePHASE4

Conditions

Parkinson's Diseaseverified · MONDO: Parkinson disease

Interventions

Rasagiline/PlaceboDRUG

RasagilineDRUG · verified · RxNorm: rasagiline

Sponsors & collaborators

Georgetown Universitylead sponsor

Teva Neuroscience, Inc.collaborator

Mapped research locations

Washington D.C.District of Columbia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01497652 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.